Experimental Treatments for Myasthenia Gravis

Batoclimab

Batoclimab is a fully human monoclonal antibody being investigated for the treatment of autoimmune diseases such as MG. It is currently being tested in Phase 2 trials.

Learn more

CFZ533

CFZ533 is designed to blocs immune responses that generate the antibodies responsible for causing muscle weakness. It is currently being tested in Phase 2 trials in moderate to severe MG.

Learn more

DAS-MG

DAS-MG (GTP-004) is an investigational medication being developed to treat muscle weakness associated with myasthenia gravis. It is currently in Phase 2 trials. 

Learn more

Efgartigimod

Efgartigimod (ARGX-113) is designed to work by decreasing the number of circulating autoantibodies in autoimmune diseases such as MG. It is currently under FDA review for the treatment of generalized MG. 

Learn more

Firdapse

Firdapse (amifampridine) is being developed to treat muscle weakness in a rare type of MG called MuSK-MG. It is currently in Phase 3 trials in these patients.

Learn more

Myasterix

Myasterix (CV-MG01) is an investigational therapeutic vaccine intended to alleviate the symptoms of myasthenia gravis. It was most recently tested in a Phase 1 trial. A Phase 2/3 trial was planned but was withdrawn due to issues with recruitment.

Learn more

Nipocalimab

Nipocalimab is a therapeutic antibody that is designed to block the activity of FcRn, a protein that normally helps to prevent IgG antibodies circulating in the bloodstream from being degraded. In so doing, the therapy aims to reduce their levels in the bloodstream and ease MG severity. A Phase 3 clinical trial is currently being conducted.

Learn more

Rituximab

Rituximab is designed to target a protein called CD-20 that is present in B-cells, which are harmful in MG. It is currently in Phase 3 trials.

Learn more

Rozanolixizumab

Rozanolixizumab (UCB7665) is an investigational humanized monoclonal immunoglobulin G antibody. It is currently in Phase 3 trials for generalized MG.

Learn more

Subcutaneous Immunoglobulin

Subcutaneous immunoglobulin, a new formulation of immunoglobulin, is given as an under-the-skin injection using a portable infusion pump. It is under investigation for MG treatment in Phase 3 trials.

Learn more

Zilucoplan

Zilucoplan is a small, synthetic molecule that is designed to bind and inhibit portions of the immune system called the complement system. It is being tested in Phase 3 trials for generalized MG.

Learn more
Books icon

Your Myasthenia Gravis Community

Visit the Myasthenia Gravis News forums to connect with others in the myasthenia gravis community. These forums are designed for patients, caregivers, and medical professionals to discuss issues, ask questions, and share experiences.

View Forums
Speech bubble icon